Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia
NCT ID: NCT00124891
Last Updated: 2022-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
500 participants
INTERVENTIONAL
2005-06-01
2006-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating GAP-486 in Heart Rhythm
NCT00137293
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
NCT00137332
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
NCT00510029
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
NCT01505296
A Study of Strategies for Electrical Isolation of Pulmonic Veins for Curative Treatment of Atrial Fibrillation
NCT00434694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Double-blind investigational anti-arrhythmic
GAP-486
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a documented history of coronary artery disease or left ventricular dysfunction
* Patients who have experienced an episode of non-sustained ventricular tachycardia within 24 hours of the index ischemic event
Exclusion Criteria
* Patients who have taken another antiarrhythmic medication (other than a beta blocker) within 5 half-lives of the start of test article
* Patients who have a history of torsades de pointes, long QT syndrome, QTc \> 0.50
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor, MD
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Merced, California, United States
Melbourne, Florida, United States
Orlando, Florida, United States
Peoria, Illinois, United States
Iowa City, Iowa, United States
Norfolk, Virginia, United States
Curitiba, Paraná, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
São José, Rio Preto, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
Salvador, , Brazil
Calgary, Alberta, Canada
Surrey, British Columbia, Canada
Newmarket, Ontario, Canada
Oshawa, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Saint-Hyacinthe, Quebec, Canada
Sherbrooke, Quebec, Canada
Terrebonne, Quebec, Canada
Moose Jaw, Saskatchewan, Canada
Multiple Locations, , Croatia
Copenhagen, , Denmark
Copenhagen South, , Denmark
Frederiksberg, , Denmark
Tószegi U. 21., H-5004 Szolnok, Hungary
Nyíri U. 38., H-6000 Kecskemét, Hungary
Markusovszky U. 3., H-9700 Szombathely, Hungary
Seregélyesi, Székesfehérvár, Hungary
Hyderabad, Andhra Pradesh, India
Thellakom, Kottayam, India
Bāndra, Mumbai, India
Multiple Locations, New Delhi, India
Rajasthan, Rajasthan, India
Multiple Locations, , India
Multiple Locations, Pisa, Italy
Genova, , Italy
Multiple Locations, , Italy
Roma, , Italy
México, D.F., Mexico
Libertad, Guadalajara Jalisco, Mexico
Multiple Locations, Guadalajara Jalisco, Mexico
Zapopan, Guadalajara Jalisco, Mexico
Monterrey, Nuevo León, Mexico
Padilla, Veracruz, Mexico
Tlalpan, , Mexico
Ostrowiec Świętokrzyski, , Poland
Piotrkow Trybunalski, , Poland
Warsaw, , Poland
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Belgrade, , Serbia
Kamenitz, , Serbia
Gothenburg, , Sweden
Kiev, , Ukraine
Kyiv, , Ukraine
Kyiv, , Ukraine
Odesa, , Ukraine
Newcastle upon Tyne, , United Kingdom
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3163K1-200
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.